Reimagining Medicine Q2 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
STRATEGY
Recent deals to bolster pipeline and strengthen technology platforms
including late stage assets in IgAN, early stage asset in CNS
Announced acquisitions (selected)
Clinical stage: IgAN1
CHINOOK™
THERAPEUTICS
Atrasentan, Ph3 oral ERA,
pivotal readout expected Q4 2023
Zigakibart, SC anti-APRIL,
expected to enter Ph3 in H2 2023
Both have shown strong
proteinuria reduction in Ph2
USD 3.2bn upfront
(total consideration up to USD 3.5bn)
Announced divestment
Neuromuscular + technology
Non-core front of eye assets¹
DTX
PHARMA
Lead early asset DTx1252
for Charcot-Marie-Tooth disease
siRNA FALCON platform
USD 0.5bn upfront
Others
Gene Therapy: Avrobio cystinosis program
RLT: Ph1/2 FAP-2286 (Clovis Oncology)
1. Subject to customary closing conditions; closing expected H2 2023
APRIL - a proliferation inducing ligand.
BAUSCH + LOMB
incl. Xiidra, SAF312, OJL332
Supports focus in 5 TAs
USD 1.75bn upfront
(total consideration up to USD 2.5bn)
Termination
BeiGene option agreement for
ociperlimab
ERA endothelin A receptor antagonist. FALCON - fatty acid ligand conjugated oligonucleotides. IgAN - immunoglobulin A nephropathy.
17 Investor Relations | Q2 2023 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation